Mounjaro Side Effects: What to Expect and How to Cope

Most Mounjaro side effects are gastrointestinal. In the SURMOUNT-1 trial, nausea occurred in roughly 24.6-33.3% of participants, diarrhoea in roughly 18.7-23.0% and vomiting in roughly 8.3-12.2%, depending on the dose studied. These are mostly mild to moderate, appear early or during dose increases, and generally ease as the body adjusts.

Why does Mounjaro cause nausea?

Nausea is not a sign that your body is rejecting the medication — it follows directly from how the drug works. Tirzepatide acts on the GIP and GLP-1 receptors, which not only signal fullness to the brain but also slow the stomach’s emptying so food stays there longer.

When food remains in the stomach longer than your body is used to, fullness, upper abdominal discomfort and nausea follow, particularly if you eat the same portions as before starting, or eat food that is already slow to digest such as fried and fatty meals. The same mechanism explains both the constipation and the diarrhoea seen in different people.

Because the effect follows the mechanism directly, symptoms tend to track the dose: the higher the dose, the more frequently symptoms are reported. This is precisely why prescribing guidance starts low and increases gradually rather than beginning at a high dose.

How common are the side effects?

The figures below come from SURMOUNT-1, which followed participants with obesity or overweight for 72 weeks.

The figure worth reading alongside these is how many people could not tolerate the medication. Across the SURMOUNT trials, roughly 4-10.5% discontinued because of adverse events, against 2.1-4% on placebo. In other words, most people who experience symptoms continue treatment after the adjustment period — having side effects does not automatically mean stopping.

These effects are broadly characteristic of the drug class rather than unique to Mounjaro.

How long do side effects last?

The common pattern is symptoms peaking in the first few days after the first injection at each dose level, then easing over one to two weeks as the body adapts. When your doctor next increases the dose, symptoms may briefly return and then settle again in the same way.

This is what makes regular follow-up meaningful. If symptoms during a dose increase are severe enough to disrupt normal life, your doctor can hold the current dose for longer before stepping up again, which often gets people through this phase without stopping. Duration and severity vary between individuals, and there is no single timeline that applies to everyone.

Easing gastrointestinal symptoms

The following self-care measures align with how the medication works. Use them alongside the advice from the doctor treating you.

1. Eat smaller meals more often instead of three large ones, since the stomach now empties more slowly
2. Chew slowly and stop when you first feel full — the fullness signal arrives sooner than you are used to
3. Avoid greasy, fried and heavily spiced food during the adjustment period, as these digest slowly and provoke symptoms
4. Sip water through the day rather than drinking large volumes at once, to avoid dehydration without feeling bloated
5. Do not lie down immediately after eating, to reduce fullness and reflux
6. Increase fibre gradually if constipated, with enough water alongside
7. Eat enough protein, because as total intake falls the risk of losing muscle mass rises

Which symptoms need a doctor straight away?

Ordinary gastrointestinal symptoms are expected. Some signs, however, should not be watched and waited on.

• Severe persistent abdominal pain, especially upper abdominal pain radiating through to the back, which can signal pancreatitis
• Vomiting or diarrhoea severe enough to cause dehydration — noticeably reduced urination, dizziness, palpitations
• Right upper abdominal pain with yellowing of the skin or eyes, which may involve the gallbladder
• A lump in the neck, difficulty swallowing, or persistent hoarseness
• Allergic reactions such as hives, swelling of the face or mouth, or difficulty breathing
• Low blood sugar, particularly in people also taking insulin or sulfonylureas

Knowing this list does not mean these will happen. It means you can tell the difference between the normal adjustment period and something that warrants contacting your doctor before the next injection.

Who needs particular caution before starting?

Groups requiring detailed assessment, or for whom this medication may not be appropriate, include people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, people with a history of pancreatitis, people with gastrointestinal disease involving pre-existing delayed gastric emptying, people with an eating disorder, people who are pregnant or breastfeeding, and people with poorly controlled liver or kidney disease.

People already taking diabetes medications — especially insulin and sulfonylureas — must tell their doctor, as existing doses may need adjusting to reduce the risk of low blood sugar. The same applies to people taking oral contraceptives, since absorption may change while gastric emptying is slowed.

Reducing the chance of side effects

The principle that helps most is titrating the dose slowly under medical supervision. At Onnyx Clinic the doctor starts at a low dose so the body can adjust gradually; the clinic stocks 2.5 mg pens as the starting dose and 5 mg as the step-up dose based on response. Mounjaro pens start at 2,499 THB.

What makes a treatment plan safer is keeping follow-up appointments, reporting symptoms honestly, and not adjusting the dose yourself. If you are already using the medication and have symptoms you are unsure about, or are considering starting, consult a doctor at Onnyx Clinic for an individual assessment. Ask via LINE: @onnyxclinic

References

• Tirzepatide Once Weekly for the Treatment of Obesity — SURMOUNT-1 (NEJM)
• Gastrointestinal tolerability and weight reduction with tirzepatide in SURMOUNT-1 to -4 (Diabetes, Obesity and Metabolism)
• Lilly: SURMOUNT-1 results published in NEJM
• Tirzepatide for overweight and obesity management (Expert Opinion on Pharmacotherapy)
• Thai Food and Drug Administration